Podcasts about young investigator award

In this insightful episode of The Hamilton Review Podcast, Dr. Bob Hamilton welcomes Professor Eva Telzer, Professor of Psychology and Neuroscience at the University of North Carolina at Chapel Hill, for an important conversation about adolescent brain development and the impact of social media on today's youth. Drawing from her article for the American Psychological Association, Professor Telzer explains how the teenage brain is uniquely shaped by social experiences, why social media can be both beneficial and harmful, and what current neuroscience reveals about the ways digital platforms influence behavior, emotions, and decision-making during adolescence. Parents, educators, and caregivers will gain valuable insights into how social media interacts with the developing brain, the role of peer relationships in teen development, and practical considerations for helping young people navigate an increasingly connected world. This thoughtful discussion offers evidence-based guidance for understanding the challenges and opportunities facing adolescents in the digital age. Eva Telzer is a Professor of Psychology and Neuroscience at UNC Chapel Hill. She is an Associate Editor for the leading journals of the field, including Child Development, Social Cognitive Affective Neuroscience, and Brain and Environment. Her research examines how social and cultural processes shape adolescent brain development, with a focus on both prosocial and risk-taking behaviors, family and peer relationships, and the role of the digital environment in youth's lives. Her research has been continuously funded for over two decades by numerous agencies and foundations including the National Institutes of Health, the National Science Foundation, the Templeton Foundation, and the Jacobs Foundation. She has authored more than 200 scientific manuscripts and book chapters and has received numerous awards for her work including an Association for Psychological Science Rising Star Award, an early career award from the Society of Research on Adolescence, a Young Investigator Award from the Flux Congress Society for Developmental Cognitive Neuroscience, and the American Psychological Association Distinguished Scientific Award for Early Career Contribution to Psychology. She is regularly featured as an expert in psychological science in consultation to government agencies and non-profit associations as well as media appearances in The New York Times, NPR, CNN, ABC, CBS, and NBC.   How to contact Professor Eva Telzer:   Professor Eva Telzer     How to contact Dr. Bob: Dr. Bob on YouTube: https://www.youtube.com/channel/UChztMVtPCLJkiXvv7H5tpDQ Dr. Bob on Instagram: https://www.instagram.com/drroberthamilton/ Dr. Bob on Facebook: https://www.facebook.com/bob.hamilton.1656 Dr. Bob's Seven Secrets Of The Newborn website: https://7secretsofthenewborn.com/ Dr. Bob's website: https://roberthamiltonmd.com/ Pacific Ocean Pediatrics: http://www.pacificoceanpediatrics.com/  

Drs. Yiu and Emami wrap-up their discussion of the 49th Annual Macula Society Meeting, focusing on new and emerging treatments for retinal diseases—such as gene therapies and longer‑acting eye injections—and reflect on both their promise and current limitations. They note that while these advances, along with tools like AI and multi-omics, are exciting, they are only beginning to influence everyday clinical practice and patient counseling.

***Mein neues Buch „Alles wird gut – aber nicht von alleine" erscheint bald und kann jetzt schon vorbestellt werden. Darin teile ich meine wichtigsten Erkenntnisse rund um ein langes, gesundes und selbstbestimmtes Leben. Hier kannst du es vorbestellen: https://link.stayoung.de/alleswirdgut***In dieser Folge spreche ich mit Dr. Tomas Bothe, Experte für Hypertonie und kardiovaskuläre Physiologie in Berlin, der für seine Arbeiten zur Qualität der Blutdruckmessung mit dem Young Investigator Award der Europäischen Dachgesellschaft für Hypertonie ausgezeichnet wurde. Bluthochdruck ist einer der wichtigsten Risikofaktoren für gesundes Altern, und doch wird er oft unterschätzt, weil er lange keine Beschwerden macht. Wir klären, welche Werte heute als optimal gelten, warum der Blutdruck mit den Jahren steigt und was im Körper passiert, wenn die Gefäße versteifen. Vor allem aber geht es um die entscheidende Frage, wie wir richtig messen: Wo die klassische Oberarm-Manschette an ihre Grenzen stößt, warum so viele Messungen fehlerhaft sind und welche Rolle neue, kontinuierliche Verfahren per Wearable künftig spielen könnten. Eine Folge für alle, die ihre Gefäßgesundheit selbst in die Hand nehmen und lange fit bleiben wollen. In dieser Folge sprechen wir u.a. über folgende Themen: Warum gilt heute 120 zu 80 als Richtwert und was hat sich gegenüber früher verändert? Weshalb wird Bluthochdruck so oft unterschätzt, obwohl er ein zentraler Risikofaktor ist? Wie viele Menschen in Deutschland sind betroffen und wie viele wissen gar nichts davon?Was passiert im Körper, wenn die Blutgefäße mit dem Alter versteifen? Welche Rolle spielen Lebensstil, Salz und Veranlagung beim Blutdruck? Wie wirken Blutdrucksenker und warum kombiniert man heute meist mehrere Wirkstoffe?Wie berechtigt ist die Angst vor Nebenwirkungen einer Blutdrucktherapie? Welche Organe leiden besonders unter zu hohem Blutdruck? Warum stößt die klassische Oberarm-Manschette bei der Messung an ihre Grenzen? Wie misst man den Blutdruck eigentlich korrekt und welche Fehler sind am häufigsten? Was leistet die kontinuierliche Blutdruckmessung per Wearable und wo steht die Forschung? Ab welchem Alter und wie häufig sollte man seinen Blutdruck überhaupt messen? Weitere Informationen zu Dr. Tomas Bothe findest du hier: LinkedIn: linkedin.com/in/md-bothe Du interessierst dich für Gesunde Langlebigkeit (Longevity) und möchtest ein Leben lang gesund und fit bleiben, dann folge mir auch auf den sozialen Kanälen bei Instagram, TikTok, Facebook oder YouTube. https://www.instagram.com/nina.ruge.official https://www.tiktok.com/@nina.ruge.official https://www.facebook.com/NinaRugeOffiziell https://www.youtube.com/channel/UCOe2d1hLARB60z2hg039l9g Disclaimer: Ich bin keine Ärztin und meine Inhalte ersetzen keine medizinische Beratung. Bei gesundheitlichen Fragen wende dich bitte an deinen Arzt/deine Ärztin. STY-287

This episode features Dr. Aayushi Uberoi PhD from Washington University in St. Louis (USA), speaking about the skin microbiome and various techniques for studying it. The skin is a reactive interface that protects the body, with the skin on various parts of the body looking very different because of stratifications in the epithelial layers and the local nutritional landscape. The skin microbiome in general is nutrient sparse and varies at different body sites. Research has shown that epithelial development, stratification, and differentiation are altered in the absence of the microbiota, showing the active role of the skin microbiota in regulating skin function. Microbes that inhabit the skin are shown to elicit unique immune responses with systemic effects. Communication between skin microbes and human body cells may be happening via metabolites. When conducting skin microbiome experiments, controls are important; the low biomass samples are susceptible to contamination. In the future, knowing more about the nutritional needs of the skin microbes could help guide the development of prebiotics for skin. Episode abbreviations and links: Paper showing a humanized mouse model for studying the skin microbiome: Commensal-derived tryptophan metabolites fortify the skin barrier: insights from a 50-species gnotobiotic model of human skin microbiome Paper on the skin microbiome's contributions to wound healing: The wound microbiota: microbial mechanisms of impaired wound healing and infection Paper investigating mechanisms of how skin microbes influence skin function: Commensal Microbiota Regulates Skin Barrier Function And Repair Via Signaling Through The Aryl Hydrocarbon Receptor Review by Belkaid and Segre: Dialogue between skin microbiota and immunity About Dr. Aayushi Uberoi PhD: Aayushi Uberoi is an Assistant professor of Pathology & Immunology and Medicine (Dermatology) in Washington University School of Medicine in Saint Louis. Her lab studies the host-microbe-environment interactions in regulating skin barrier. She has studied interactions between microbes and skin since her Ph.D. research on cutaneous papillomaviruses in Dr. Paul Lambert's lab at the University of Wisconsin-Madison. While traditional studies of infectious skin diseases have typically focused on singular pathogens within the host, skin is colonized by a diverse array of microbes, which likely exert significant influence on epithelial characteristics. Motivated by this question, Aayushi’s postdoctoral research at the University of Pennsylvania in Dr. Elizabeth Grice's lab explored the role of the commensal microbiome in regulating the function of the cutaneous barrier. In the lab, Aayushi wears several hats such as conducting research, developing protocols and assays, writing, and making sure the lab has fun equipment. Aayushi is a recipient of K99/R00 Pathway to Independence award from National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS/NIH), innovator award from Society of Investigative Dermatology, fellowships from Prevent Cancer Foundation and Dermatology Foundation and a Young Investigator Award from the Wound Healing Society. 

Dr. Uri Tabori is a Staff Physician in the Division of Haematology/Oncology, Senior Scientist in the Genetics & Genome Biology program, and Principal Investigator of The Arthur and Sonia Labatt Brain Tumour Research Centre at The Hospital for Sick Children (SickKids). Uri is also a Professor in Paediatrics and Associate Professor in the Institute of Medical Sciences at the University of Toronto. Uri works as a physician treating kids with cancer, particularly brain tumors. Through his research, he is working to identify drugs and make new discoveries that may cure cancers or improve patients' lives. When he's not hard at work in the lab or clinic, Uri enjoys spending time with his family, watching American football, and exploring the wilderness of Canada. He is especially fond of canoeing and canoe camping with his family. He received his MD from the Hadassah School of Medicine of Hebrew University in Israel. Afterwards, he completed a Rotating Internship and his Residency in Pediatrics at the Sorasky Medical Center in Israel. Next, Uri accepted a Fellowship in Pediatric Hematology and Oncology at the Sheba Medical Center in Israel. He served as a Staff Physician in Pediatric Hematology and Oncology at The Sheba Medical Center for about a year before accepting a Research and Clinical Fellowship at The Hospital for Sick Children in Canada SickKids where he remains today. Over the course of his career, Uri has received numerous awards and honors, including the Early Researcher Award from the Ontario Ministry of Development and Innovation, the New Investigator Award from the Canadian Institute of Health Research, the Junior Physician Research Award from the University of Toronto Department of Pediatrics, The New Investigator Award from the Terry Fox Foundation, A Eureka! new investigator award from the International Course of Translational Medicine, A Merit Award from the American Society of Clinical Oncology Annual Meeting, and The Young Investigator Award from the Canadian Neuro-Oncology Society. In our interview, Uri shares more about his life, science, and clinical care.

Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors of the latest articles published in the Journal of Clinical Oncology. I'm your host, Dr. Davide Soldato, a medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by Dr. Lin, assistant professor in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Dr. Lin and I will be discussing the article titled, "Racial and Ethnic Disparities Along the Treatment Cascade Among  Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." Thank you for speaking with us, Dr. Lin. Dr. Lin: Thank you so much for having me. I appreciate it. Dr. Davide Soldato: So, just to start, to frame a little bit the study, I just wanted to ask you what prompted you and your team to look specifically at this question - so, racial and ethnic disparities within this specific population? And related to this question, I just wanted to ask how this work is different or builds on previous work that has been done on this research topic. Dr. Lin: Yeah, absolutely. Part of the impetus for this study was the observation that despite people who are black or Hispanic having equivalent health insurance status - they all have  Medicare Fee-for-Service - we've known that treatment and survival differences and disparities have persisted over time for patients with metastatic breast, colorectal, lung, and prostate cancer. And so, the question that we had was, "Why is this happening, and what can we do about it?" One of the reasons why eliminating racial and ethnic disparities in survival among Medicare beneficiaries with metastatic cancer has been elusive is because these disparities are occurring along a lot of dimensions. Whether or not it's because the patient presented late and has very extensive metastatic cancer; whether or not the patient has had a difficult time even seeing an oncologist; whether or not the patient has had a difficult time starting on any systemic therapy; or maybe it's because the patient has had a difficult time getting guideline-concordant systemic therapy because, more recently, these treatments have become so expensive. Disparities, we know, are occurring along all of these different facets and areas of the treatment cascade. Understanding which one of these is the most important is the key to helping us alleviate these disparities. And so, one of our goals was to evaluate disparities along the entire treatment cascade to try to identify which disparities are most important. Dr. Davide Soldato: Thank you very much. That was very clear. So, basically, one of the most important parts of the research that you have performed is really focusing on the entire treatment cascade. So, basically, starting from the moment of diagnosis up to the moment where there was the first line of treatment, if this line of treatment was given to the patient. So, I was wondering a little bit, because for this type of analysis, you used the SEER-Medicare linked database. So, can you tell us a little bit which was the period of time that you selected for the analysis? Why do you think that that was the most appropriate time to look at this specific question? And whether you feel like there is any potential limitation in using this type of database and how you handled this type of limitations? Dr. Lin: Yeah, absolutely. It's a great question. And I want to back up a little bit because I want to talk about the entire treatment cascade because I think that this is really important for our research and for future research. We weren't the first people to look at along the treatment cascade for a disease. Actually, this idea of looking along the treatment cascade was pioneered by HIV researchers and has been used for over a decade by people who study HIV. And there are a lot of parallels between HIV and cancer. One of them is that with HIV, there are so many areas along that entire treatment cascade that have to go right for somebody's treatment to go well. Patients have to be diagnosed early, they have to be given the right type of antiretrovirals, they have to be adherent to those antiretrovirals. And if you have a breakdown in any one of those areas, you're going to have disparities in care for these HIV patients. And so, HIV researchers have known this for a long time, and this has been a big cornerstone in the success of getting people with HIV the treatment that they need. And I think that this has a lot of parallels with cancer as well. And so, I am hoping that this study can serve as a model for future research to look along the entire treatment cascade for cancer because cancer is, similarly, one of these areas that requires multidisciplinary, complex medical care. And understanding where it is breaking down, I think, is crucial to us figuring out how we can reduce disparities. But for your question about the SEER-Medicare linked database, so we looked between 2016 and 2019. That was the most recent data that was available to us. And one of the reasons why we were excited to look at this is because there were some new treatments that were just released and FDA-approved around 2018, which we were able to study. And this included immunotherapy for non–small cell lung cancer, and then it also included androgen receptor pathway inhibitors, the second-generation ones, for prostate cancer. And the reason why this is important is because for some time, as we have developed these new therapies, there's been a lot of concern that there have been disparities in access to these novel therapies because of how expensive they are, particularly for the Medicare population. And so one of the reasons why we looked specifically at this time period was to understand whether or not, in more recent years, these novel therapies, people are having increasing disparities in them and whether or not increasing disparities in these more expensive, newer therapies is contributing to disparities in mortality. That being said, obviously, we're in 2025 and these data are by now six years old, and so there are additional therapies that are now available that weren't available in the past. But I think that, that being said, at least it's sort of a starting point for some of the more important therapies that have been introduced, at least for non–small cell lung cancer and prostate cancer. And the database, SEER-Medicare, is helpful because it uses the population cancer registry, which is the SEER registry cancer registry, linked to Medicare claims. So, any type of medical care that's billed through Medicare, which is going to basically be all of the medical care that these patients receive, for the most part, we're going to be able to see it. And so, I think that this is a really powerful database which has been used in a lot of research to understand what kind of care is being received that has been billed through Medicare. So, one of the limitations with this database is if there is care that's received that was not billed through Medicare, we're not going to be able to see that. And this does not happen probably that frequently, particularly because most patients who have insurance are going to be receiving care through insurance. However, we may see it for some of the oral Part D drugs. Some of those drugs are so expensive that patients cannot pay for the coinsurance during that time. And it's possible that some of those drugs patients were getting for free through the manufacturer. We potentially missed some of that. Dr. Davide Soldato: So, going a little bit into the results, I think that these are very, very interesting. And probably the most striking one is that when we look at the receipt of any type of treatment for metastatic breast, colorectal, prostate, and lung cancer - and specifically when we look at guideline-directed first-line treatments - you observed striking differences. So, I just wanted you to guide us a little bit through the results and tell us a little bit which of the numbers surprised you the most. Dr. Lin: So, what we were expecting is to see large disparities in receiving what we called guideline-directed systemic therapy. And guideline-directed systemic therapy during this time kind of depended on the cancer. So, we thought that we were going to see large disparities in guideline-directed therapy because these were the more novel therapies that were approved, and thus they were going to be the more expensive therapies. And so, what this meant was for colorectal cancer, this was going to be any 5-FU–based therapy. For lung cancer, this was going to be any checkpoint inhibitor–based therapy. For prostate cancer, this was going to be any ARPI, so this was going to be things like abiraterone or enzalutamide. And for breast cancer, this was going to be CDK4 and 6 TKIs plus any aromatase inhibitor. And so, for instance, for breast, prostate, and lung cancer, these were going to be including more expensive therapies. And so, what we expected to see was large disparities in receiving some of these more expensive, novel therapies. And we thought we were going to see fewer disparities in receiving some of the cheaper therapies, such as aromatase inhibitors, 5-FU, older platinum chemotherapies for lung cancer, and ADT for prostate cancer. We were shocked to find that we saw large racial and ethnic disparities in seeing some of the older, cheaper chemotherapies and hormonal therapies. So for instance, for breast cancer, 59% of black patients received systemic therapy, whereas 68% of white patients received systemic therapy. For colorectal, only 23% of black patients received any systemic therapy versus 34% of white patients. For lung, only 26% of black patients received any therapy, whereas 39% of white patients did. And for prostate, only 56% of black patients received any systemic therapy versus 77% of white patients. And so, we were pretty shocked by how large the disparities were in receiving these cheap, easy-to-access systemic therapies. Dr. Davide Soldato: Thank you very much. So, I just wanted to go a little bit deeper in the results because, as you said, there were striking differences even when we looked at very old and also cheap treatments that, for the majority of the patients that were included inside of your study, were actually basically available for a very small price to these patients who had the eligibility for Medicare or Medicaid. And I think that one of the very interesting parts of the research was actually the attention that you had at looking how much of these disparities could be explained by several factors. And actually, one of the most interesting results is that you observed that low-income subsidy status was actually a big determinant of these disparities in terms of treatment. So, I just wanted to guide us a little bit through these results and then just your opinion about how these results should be interpreted by policymakers. Dr. Lin: Yeah, absolutely. I'm going to explain a little bit about what low-income subsidy status is and dual-eligibility status. Some of the listeners may not know what low-income subsidy status or dual-eligibility status is. Low-income subsidy status is part of Medicare Part D. Medicare Part D is an insurance benefit that allows patients to receive oral drugs. So these are drugs that are dispensed through the pharmacy, such as the CDK4/6 inhibitors, as well as second-generation ARPIs in our study. For patients who have Medicare Part D and whose income is low enough - falls below a certain federal poverty level threshold - those patients will receive their oral drugs for much cheaper. And this is really important for some of these more novel therapies because for some of these more novel therapies, if you don't have low-income subsidy status, you may be paying thousands of dollars for a single prescription of those drugs. Whereas if you have low-income subsidy status, you may be paying less than $10. And so that difference, greater than $1,000 or $2,000 versus less than $10, one would think that the patient who's paying less than $10 would be much more likely to receive those therapies. So that's low-income subsidy status. Low-income subsidy status, importantly, doesn't apply for infused medications like immunotherapy. But it's important to know that most people with low-income subsidy status - about 88% - are also dual-eligible. What dual-eligible means is that they have both Medicare and Medicaid. Medicare being the insurance that everybody has in our study who's greater than 65. And Medicaid is the state-run but federally subsidized insurance that patients with low incomes have. And so patients who are dual-eligible - and about 87% of those with low-income subsidy status are dual-eligible - those patients have both Medicaid and Medicare, and they basically pay next to nothing for any of their medical care. And that's because Medicare will reimburse most of the medical care and the copays or coinsurance are going to be covered by Medicaid. So Medicaid is going to pick up the rest of the bill. So, most of the patients who have low-income subsidy status who are dual-eligible, these patients pay almost nothing for their medical care - Part B or Part D, any of their drugs. And so, one would expect that if cost were the main determinant of disparities in cancer care, then one would expect that dual-eligibles, most of them would be receiving treatment because they're facing minimal to no costs. What we found is that when we broke down the racial and ethnic disparity by a number of factors - including LIS status/dual eligibility, age, the number of comorbidities, etcetera - what we found was that the LIS or dual-eligibility status explained about 20% to 45% of the disparities that we saw in receiving treatment. And what that means is despite these patients paying next to nothing for their drugs, these are the most likely patients to not be treated for their cancer at all. So they're most likely to basically be diagnosed, survive for two months, see an oncologist, and then never receive any systemic therapy for their cancer. And this is not just chemotherapies for colorectal or lung cancer. This includes cheaper, easier-to-tolerate hormonal therapies that you can just take at home for breast cancer, or you can get every six months for prostate cancer, that people who even have poorer functional status are able to take. However, for whatever reason, these dual-eligible or LIS patients are very unlikely to receive treatment compared to any other patient. The low likelihood of treating this group of patients, that explains a large portion of the racial and ethnic disparities that we see. Dr. Davide Soldato: And one thing that I think is very interesting and might be of potential interest to our listeners is, did you compare survival outcomes in these different settings? And did you observe any significant differences in terms of racial and ethnic disparities once you saw that there was a significant difference when looking at both receipt of any type of treatment and also guideline-directed treatments? Dr. Lin: We saw that there were large disparities in survival by race and ethnicity when you look overall. However, when you just account for the patients who received any systemic therapy at all - not just guideline-directed systemic therapy - those differences in survival essentially disappeared. And so, what that suggests is that if black patients were just as likely to receive any systemic therapy at all as white patients, we would expect that the survival differences that we were seeing would disappear. And this is not even just looking at guideline-directed systemic therapy. This was looking just at systemic therapy alone. And so, while guideline-directed systemic therapy should be a goal, our research suggests that if we are to close the gap in disparities in overall survival among black and white patients, we must first focus on patients just receiving any type of treatment at all. And that should be the very first focus that policymakers, that leaders in ASCO, that health system leaders, that physicians, that we should focus on: just trying to get any type of treatment to our patients who are poorer or black. Dr. Davide Soldato: Thank you very much. And this was not directly related to the research that you performed, but going back to this very point - so, increasing the number of patients that receive any kind of systemic treatment before looking at guideline-directed treatments - what would you feel would be the best way to approach this in order to decrease the disparities? Would you look at interventions such as financial navigation or maybe improving referral pathways or providing maybe more culturally adapted information to the patients? Because in the end, what we see is disparities based on racial and ethnicity. We see that we can reduce these disparities if we get these patients to the treatment. But in the end, what would you feel is the best way to bring patients to these types of treatments? Dr. Lin: I think the most important thing is to understand that these disparities are not primarily happening because of the high cost of cancer treatment. These disparities are happening because of other social vulnerabilities that these patients are facing. And so these vulnerabilities could be a lot of things. It could be mistrust of the medical system. It could be fear of chemotherapy or other treatments. It could be difficulty taking time off of work. It could be any number of things. What we do know is when we've looked at the types of interventions that can help patients receive treatment, navigation is probably the most effective one. And the reason why I think that is because when patients don't receive treatment because of social vulnerability, I sort of look at social vulnerability like links in a chain. Any weakest link is going to result in the patient not receiving treatment. This may be because they have a hard time taking time off of work. This may be because they had a hard time getting transportation to their physician. It may be because they had an interaction with a physician, but that interaction was challenging for the patient. Maybe they mistrusted the physician. Maybe they're worried about the medical system. If any of these things goes wrong, the patient is not going to be treated. The patient navigator is the only person who can spot any of those weak links within the chain and address them. And so, I think that the first thing to do is to get patient navigation systems in place for our vulnerable patients throughout the United States. And this is incredibly important because in Medicare, patient navigation is reimbursable. And so this is not something that's ‘pie in the sky'. This is something that's achievable today. The second thing is that it's really important that we see these vulnerabilities happening for patients who are dual-eligible, who have both Medicare and Medicaid. One of the reasons why this is important is because there has been a lot of research outside of what we've done that has shown vulnerabilities for dual-eligible patients who have Medicare for a number of different diseases. And the reason why is because, although patients are supposed to have the benefits of both Medicare and Medicaid, usually these two insurances do not play nicely together. It creates a huge, bureaucratic, complex mess and maze that most of these patients are unable to navigate. And so many of these patients are unable to actually receive the full reimbursement from both Medicare and Medicaid that they should be getting because those two insurers are not communicating well. And so the second thing is that national cancer organizations need to be supporting policies and legislation that is already being discussed in Congress to revamp the dual-eligible system so that it facilitates these patients getting properly reimbursed for their care from both Medicare and Medicaid and these systems working together well. The third thing is that Medicaid itself has many benefits that can allow patients to receive care, like they have transportation benefits so that patients can get to and from their doctor's appointments with ease. And so I think this will be additionally very, very helpful for patients. The last thing is, you know, it's possible that future innovations such as telemedicine and tele-oncology and cancer care at home can also make it easier for some of these patients who may be working a lot to receive care. But what I would say is that our study should be a call for healthcare delivery researchers to start piloting interventions to be able to help these patients receive systemic therapy. And so what this could look like is trying to get that care navigation and implement that in clinics so that patients can be receiving the care that they need. Dr. Davide Soldato: Thank you very much. That was a very clear perspective on how we can tackle this issue. So, I just wanted to close with a sort of personal question. I was wondering what led you to work specifically in this research field that is very challenging, but I think it's particularly critical in healthcare systems like in the United States. Dr. Lin: Yeah, absolutely. One of the most important things for me as an oncologist and a researcher is being able to know that all patients in the United States - and obviously abroad - who have cancer should be able to receive the kind of care that they deserve. I don't think that patients, because their incomes are lower or because their skin looks a certain color or because they live in rural areas, these shouldn't be determinants of whether or not cancer patients are receiving the care that they need. We can develop and pioneer the very best treatments and breakthroughs in oncology, but if our patients are not receiving them - if only 20% of our patients with colon cancer or lung cancer are receiving any type of systemic therapy, who are black - this is a big problem. But this is something that I think that our system can tackle. We need to get these breakthroughs that we have in oncology to every single cancer patient in America and every single cancer patient in the world. I think this is a goal that all oncologists should have, and I think that this is something that, honestly, is achievable. I think that research is a powerful tool to give us a lens into understanding exactly why it is that certain patients are not getting the care that they deserve. And my goal is to continue to use research to shed light on why our system is not performing the way that we all want it to be. Dr. Davide Soldato: Circling back to your research, actually the manuscript that was published was supported by a Young Investigator Award by the American Society of Clinical Oncology. So, was this the first step of a more broad research, or do you have any further plans to go deeper in this topic? Dr. Lin: Yeah, absolutely. First, I want to thank the ASCO Young Investigator Award for funding this research because I think it's fair to say that this research would not have happened at all without the support of the ASCO YIA. And the fact that ASCO is doing as much as it can to support the future generation of cancer researchers is incredible. And it's a huge resource, and having it come at the time that it did is critical for so many of us. So I think that this is an unbelievable thing that ASCO does and continues to do with all of its partners. For me, yeah, this is definitely a stepping stone to further research.  Medicare Fee-for-Service is only one part of the population. I want to spread this research and extend it to patients who have other types of insurances, look at other types of policies, and also try to conduct some of the cancer care delivery research that's needed to try to pilot some interventions that can resolve this problem. So hopefully this is the first step in a broader series of studies that we can all do collectively to try to eliminate racial and ethnic disparities in cancer care and survival. Dr. Davide Soldato: So, I think that we've come at the end of this podcast. Thank you again, Dr. Lin, for joining us today. Dr. Lin: Thank you so much. It was a pleasure to be a part of this. Dr. Davide Soldato: So, we appreciate you sharing more on your JCO article, "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

  As a young person starting over in a new country—one where she didn't even yet know the language—young Yelena faced no shortage of challenges. But she also found opportunity she believes might not have existed in her native country.  “As an Armenian individual growing up in Azerbaijan, going by my parents' and my family's experience, I don't think I would have had an opportunity to be a physician there,” Dr. Janjigian says. “There was a clear limitation on who got to be a physician, and it's a prestigious position anywhere in the world. As a relative minority, I wouldn't have been able to do that. My parents certainly had the courage it took to leave and to come to a foreign country.”  That same brand of courage led Dr. Janjigian to her current work as a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center. A specialist in esophageal and stomach cancer, she presented the results of her gastric cancer clinical trial during the plenary session of this year's ASCO Annual Meeting in Chicago. The presentation was the culmination of more than eight years of work involving nearly 1,000 patients and collaborators. Much of that work, she says, started when she received her first grant from Conquer Cancer, a Young Investigator Award. Receiving that funding, she recalls, was a career-defining moment.      In this episode of Your Stories, Dr. Janjigian speaks with host Dr. Mark Lewis about her journey to become an oncologist, along with her vision for a world where a cancer diagnosis isn't nearly as frightening as it is today. 

Flexibility is a cardinal virtue in physical fitness, and according to political psychologist and neuroscientist Leor Zmigrod, it can be a cardinal virtue in our mental health, too. How she came to that conclusion and how common rigid thinking can be are themes explored in her new book, The Ideological Brain. “I think that from all the research that I've done,” she tells interviewer David Edmonds in this Social Science Bites podcast, “I feel that what rigid thinking does is it numbs people to the complexity of their own experience, and it simplifies their thinking. It makes them less free, less authentic, less expansive in their imagination.” And while she acknowledges there are times being unbending may be seen as an asset, “rigid thinking is rarely good for you at an individual level.” In this podcast, she details some of the work – both with social science experimentation and with brain imaging – that determines if people are flexible in their thinking, what are the real-life benefits of being flexible, if they can change, and how an ideological brain, i.e. a less flexible brain, affects politics and other realms of decision-making. “When you teach or when you try to impart flexible thinking, you're focusing on how people are thinking, not what they're thinking,” Zmigrod explains. “So it's not like you can have a curriculum of ‘like here is what you need to think in order to think flexibly,' but it's about teaching how to think in that balanced way that is receptive to evidence, that is receptive to change, but also isn't so persuadable that any new authority can come and take hold of your thoughts.” Zmigrod was a Gates Scholar at Cambridge University and won a winning a Junior Research Fellowship at Churchill College there. She has since held visiting fellowships at Stanford and Harvard universities, and both the Berlin and Paris Institutes for Advanced Study. Amond many honors the young scholar received are the ESCAN 2020 Young Investigator Award by the European Society for Cognitive and Affective Neuroscience, the Glushko Dissertation Prize in Cognitive Science by the Cognitive Science Society, . the 2020 Women of the Future Science Award and the 2022 Women in Cognitive Science Emerging Leader Award, and the 2022 Distinguished Junior Scholar Award in Political Psychology by the American Political Science Association. 

On this episode of the AMSSM Sports Medcast (X: @TheAMSSM), host Dr. Jeremy Schroeder, DO (X: @thejschro), is joined by two guests to discuss their award-winning research from last year's AMSSM Annual Meeting in Baltimore, MD. First, Dr. Meredith Ehn – the 2024 Young Investigator Award winner – discusses “The NICA Injury Surveillance System: Results from Five Years of Student-Athlete Injury Data,” which was recently published in Research in Sports Medicine. Then, Dr. Rajiv Jain – the 2024 NCAA Research Award winner – shares information about his study, “Assessment Of Stimulated Blink Reflex And Symptoms Over Time In Collegiate Athletes With Sport-related Concussion,” which appeared in Medicine & Science in Sports & Exercise.   Links to the Research Articles: The NICA Injury Surveillance System: Results from Five Years of Student-Athlete Injury Data https://www.tandfonline.com/doi/full/10.1080/15438627.2025.2478399 Assessment Of Stimulated Blink Reflex And Symptoms Over Time In Collegiate Athletes With Sport-related Concussion: https://journals.lww.com/acsm-msse/fulltext/2024/10001/assessment_of_stimulated_blink_reflex_and_symptoms.2413.aspx

Stefano Abbate, profesor de Filosofía Política en la Universitat Abat Oliba CEU, participa activamente en medios y espacios de pensamiento crítico. Destaca por su labor divulgativa como fundador del canal Peregrinos en Distopía y por sus publicaciones sobre gnosis, transhumanismo, sexualidad y orden político. Ha sido premiado por las Academias Pontificias de Teología y recibió el "Young Investigator Award" en 2024.Canal de Stefano - Peregrinos en Distopía: https://www.youtube.com/@PeregrinosenDistopiaEscúchanos también en:Spotify: https://open.spotify.com/show/1HI8XcuaPlOOvaMyuIoQPR?si=i58ihoeAQC6mE0QN6oTP6wApple Podcasts: https://podcasts.apple.com/es/podcast/a-la-de-tr3s/id1548687501iVoox: https://go.ivoox.com/sq/1199920Sigue a Stefano Abbate:Instagram: instagram.com/peregrinosendistopiaTelegram: t.me/PeregrinosenDistopiaTiktok: tiktok.com/@peregrinosendistopiaSpotify: https://open.spotify.com/show/5iLkO3I9xGeY462c8OsLQw?si=be4c81eae74f43a2Sigue a Aladetres:Instagram: https://www.instagram.com/aladetres.esTwitter: https://twitter.com/aladetres_esTiktok: https://www.tiktok.com/@aladetres.esFacebook: https://www.facebook.com/aladetres.esSigue a Lluís Gracia:Instagram: https://www.instagram.com/lluis_graciaTwitter: https://twitter.com/lgraciamolinsContacto: alade3podcast@gmail.comDeja tu like y tu comentario, ¡y no olvides suscribirte y darle a la campanita! :)#aladetres

Send us a textIn this conversation, Dr. Paul Offit and pediatrician Jessica Hochman discuss the importance of vaccinations, the challenges of vaccine hesitancy among parents, and the need for nuanced conversations in public health. They explore the impact of the COVID-19 pandemic on public trust, and the science behind vaccination schedules. The discussion emphasizes the importance of understanding parental concerns while advocating for the safety and efficacy of vaccines. About Paul A. Offit, MD!Paul A. Offit, MD, is Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children's Hospital of Philadelphia. He is the Maurice R. Hilleman Professor of Vaccinology at the Perelman School of Medicine at the University of Pennsylvania.Dr. Offit is an internationally recognized expert in the fields of virology and immunology, and was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention. He is a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, and a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine and co-editor of the foremost vaccine text, Vaccines.He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal.Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and he was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health.In 2009, Dr. Offit received the President's Certificate for Outstanding Service from the American Academy of Pediatrics. In 2011, he received the Humanitarian of the Year Award from the BiologicDr Jessica Hochman is a board certified pediatrician, mom to three children, and she is very passionate about the health and well being of children. Most of her educational videos are targeted towards general pediatric topics and presented in an easy to understand manner. For more content from Dr Jessica Hochman:Instagram: @AskDrJessicaYouTube channel: Ask Dr JessicaWebsite: www.askdrjessicamd.com-For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20-To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA Do you have a future topic you'd like Dr Jessica Hochman to discuss? Email Dr Jessica Hochman askdrjessicamd@gmail.com.The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditions or formulate treatment plans for specific individuals. If you have a concern about your child's health, be sure to call your child's health care provider.

How can neuroscience help us personalise mental health diagnoses and treatments? How are mental heath stats changing and why? How effective are life style changes as a prevention? What other new treatments are proving promising and effective? In this episode we're going to get an update on all the recent research from neuroscience that's studying mental health, and not just the issues and the treatments being used to deal with them, but also the importance of the brain itself in the perception of our mental health, and the lifestyle choices that can preventatively ward off the issues before they arise; things like nutrition, sleep, exercise, and social contact. We'll be looking at the big one: depression and its connection to inflammation, and a wide range of buzz therapies including psychedelic therapy and cold water immersion. Today's guest has just written a book for the public on this topic “The Balanced Brain: The science of mental health”, and her lab at MRC Cognition and Brain Sciences in Cambridge bridges the gap between the nuts and bolts of cognitive neuroscience and the more mind base of clinical psychology. She is neuroscientist and author Camilla Nord. In 2022, she was named a Rising Star by the US Association for Psychological Science, and received the Young Investigator Award from the European Society for Affective and Cognitive Science.   Now it strikes me that if we can integrate new evidence from brain research into the clinical psychology field, we‘ve got a much better shot at treating ever rising numbers of mental health diagnoses and perhaps educating a good portion of the next generation enough to avoid these issues all together. It may be a pipe dream but we've got to try. What we discuss:  00:00 Intro 07:00 Our perception of pain. 11:00 Body changes lead to mental health changes. 12:00 Our ‘Inside-out' perception is an active predictor of our mental health and the outside world. 16:00 The importance of narrative repetition to our self-perception. 18:00 Individualised data and solutions to mental health are impractical for our one-size-fits-all medical systems on a budget. 23:30 Nutritional Psychiatry - the connection between diet and mental health. 26:30 Gut-brain axis importance. 28:00 The risk of dieting affecting pleasure centres and thus motivation and mental health. 30:00 Inflammatory diet choices and lifestyle leading to depression. 33:30 Microbiome research: promise vs wishful thinking. 37:45 Social connection, nature connection and connection to meaning. 40:45 Some mental health symptoms can be useful and adaptive. 43:20 Sport and physical exercise to improve mental health. 46:00 Depression leads to a lack of drive to obtain pleasure - Anhedonia. 48:20 Sleep neuroscience. 53:30 Anger management and ‘hangriness'. 56:20 The Placebo effect is a useful part of a treatment's effect. 58:00 Changing diagnosis rates in mental health. 01:02:00 Psychedelic therapy was unpopular before the last 10 years of study. 01:06:00 MDMA's uses for PTSD, and modifying beliefs and expectations. 01:08:10 Connection between psychosis and cannabis. 01:09:20 Cannabis CBD Oil treatment of THC addiction. 01:11:15 Cold water immersion for euphoria and pain tolerance. 01:13:00 The changing nature of mental health. References: Camilla Nord, “The Balanced Brain, the Science of mental health”. Felicity Jacka, Nutritional psychiatry, Guardian Article Metabolic health influences learning paper. Clinical psychosis vs mediumship paper. Connection to symptoms changes mental health outcomes. Oliver J Robinson - Adaptive anxiety paper Wim Hof, Cold water Immersion method, list of science papers

In this episode of The Thyroid Answers Podcast, I discuss Thyroid lab tests, lab values, and the over-prescription of thyroid medication. Topics covered in this episode include:  Optimal vs Lab reference ranges Lab value vs lab interpretation The problem with optimal ranges Seasonal variability and other factors that influence TSH The over-prescription of thyroid medication and More...   Dr. Joe El-Khoury is Associate Professor of Laboratory Medicine at Yale School of Medicine and Director of the Clinical Chemistry Laboratory and fellowship program at Yale-New Haven Health. He is board-certified by the American Board of Clinical Chemistry and a fellow of the Association for Diagnostics and Laboratory Medicine Academy. He currently serves on the Editorial Boards of Clinical Chemistry and Clinical Biochemistry, as Chair of the IFCC Committee on Kidney Diseases, and on the Board of Directors for ADLM. He is the recipient of the 2023 Young Investigator Award from the International Federation for Clinical Chemistry and Laboratory Medicine. He recently launched his own YouTube channel, entitled “Clinical Chemistry with Joe El-Khoury”, which infuses science with comedy and is focused on improving laboratory medicine practice. https://www.youtube.com/@UCYuD1s42xkXSd70QSLRB6ew

Summary Dr Jenny Murphy is a senior lecturer at the University of Surrey. Here she discusses interoception and its importance in mental and physical health. Interoception refers to the processing of signals that come from inside the body, such as heart rate and breathing. People can differ in their ability to perceive these signals, as well as how much attention they pay to them and how they evaluate them. Interoception is associated with homeostasis and has been linked to various mental health conditions and higher-order cognitive abilities. Measurement of interoception is challenging but can be done through various tasks and self-report measures. Clinical applications include interoception training for anxiety and physical health conditions. Jenny discusses the role of perception and external cues in regulating the body, as well as the potential factors influencing interoception. She explains that her research focuses on measuring interoception and its development, and she is currently studying interoception across the menstrual cycle. Jenny also discusses the clinical implications of her work and the possible integration of interoception into therapy. She emphasizes the importance of interdisciplinary collaboration and the need for more research on the relationship between thoughts, feelings, and behavior. Jenny mentions her upcoming textbook on interoception and concludes by offering advice on improving well-being through the understanding and regulation of interoceptive signals. She is editing a textbook on interoception at the moment that should be published by Springer, Nature at the end of the year. Keywords interoception, signals, perception, attention, evaluation, mental health, physical health, measurement, clinical applications, perception, external cues, regulation, body, interoception, development, menstrual cycle, clinical implications, therapy, interdisciplinary collaboration, thoughts, feelings, behavior, textbook, well-being Takeaways Interoception refers to the processing of signals that come from inside the body, such as heart rate and breathing. People can differ in their ability to perceive these signals, as well as how much attention they pay to them and how they evaluate them. Interoception is associated with homeostasis and has been linked to various mental health conditions and higher-order cognitive abilities. Measurement of interoception is challenging but can be done through various tasks and self-report measures. Clinical applications of interoception include training for anxiety and physical health conditions. Perception and external cues play a role in regulating the body and compensating for imperfect interoceptive signals. Jenny's research focuses on measuring interoception and its development, with current studies on interoception across the menstrual cycle. There are limited clinical implications of interoception research at present, but it may contribute to therapies like mindfulness and cognitive-behavioral therapy. Interoception is an interdisciplinary field that can benefit from collaboration and integration with other areas of research. The relationship between thoughts, feelings, and behavior is complex and requires further investigation in the context of interoception. Jenny is working on a textbook on interoception that aims to provide an up-to-date and comprehensive resource for students and practitioners. Improving well-being through interoception involves recognizing the balance between paying attention to bodily signals and focusing on external cues. Publications https://www.jennymurphylab.com/publications Bio Jenny completed her PhD at King's College London in December 2019. Here she investigated the measurement of interoception, it's developmental trajectory and the relationship between interoception, health and higher order cognition. In April 2020 she took up a lectureship position at Royal Holloway University of London and in March 2024 she took up a senior lectureship position at the University of Surrey. Jenny's work on interoception has been recognised by several awards for doctoral contributions (from the British Psychological Society, Experimental Psychology Society and King's College London) and early career prizes (the American Psychological Society Rising Star Award and the Young Investigator Award from the European Society for Cognitive and Affective Neuroscience). Jenny is particularly interested in sex differences in interoceptive abilities, including how these emerge across development and whether they relate to sex differences in mental and physical health. She currently holds a New Investigator Grant from the Medical Research Council for investigating changes in interoception across the menstrual cycle.

Summary Dr Jenny Murphy, is a senior lecturer at the University of Surrey. Here she discusses interoception and its importance in mental and physical health. Interoception refers to the processing of signals that come from inside the body, such as heart rate and breathing. People can differ in their ability to perceive these signals, as well as how much attention they pay to them and how they evaluate them. Interoception is associated with homeostasis and has been linked to various mental health conditions and higher-order cognitive abilities. Measurement of interoception is challenging but can be done through various tasks and self-report measures. Clinical applications include interoception training for anxiety and physical health conditions. Jenny discusses the role of perception and external cues in regulating the body, as well as the potential factors influencing interoception. She explains that her research focuses on measuring interoception and its development, and she is currently studying interoception across the menstrual cycle. Jenny also discusses the clinical implications of her work and the possible integration of interoception into therapy. She emphasizes the importance of interdisciplinary collaboration and the need for more research on the relationship between thoughts, feelings, and behavior. Jenny mentions her upcoming textbook on interoception and concludes by offering advice on improving well-being through the understanding and regulation of interoceptive signals. She is editing a textbook on interoception at the moment that should be published by Springer, Nature at the end of the year. Keywords interoception, signals, perception, attention, evaluation, mental health, physical health, measurement, clinical applications, perception, external cues, regulation, body, interoception, development, menstrual cycle, clinical implications, therapy, interdisciplinary collaboration, thoughts, feelings, behavior, textbook, well-being Takeaways Interoception refers to the processing of signals that come from inside the body, such as heart rate and breathing. People can differ in their ability to perceive these signals, as well as how much attention they pay to them and how they evaluate them. Interoception is associated with homeostasis and has been linked to various mental health conditions and higher-order cognitive abilities. Measurement of interoception is challenging but can be done through various tasks and self-report measures. Clinical applications of interoception include training for anxiety and physical health conditions. Perception and external cues play a role in regulating the body and compensating for imperfect interoceptive signals. Jenny's research focuses on measuring interoception and its development, with current studies on interoception across the menstrual cycle. There are limited clinical implications of interoception research at present, but it may contribute to therapies like mindfulness and cognitive-behavioral therapy. Interoception is an interdisciplinary field that can benefit from collaboration and integration with other areas of research. The relationship between thoughts, feelings, and behavior is complex and requires further investigation in the context of interoception. Jenny is working on a textbook on interoception that aims to provide an up-to-date and comprehensive resource for students and practitioners. Improving well-being through interoception involves recognizing the balance between paying attention to bodily signals and focusing on external cues. Publications https://www.jennymurphylab.com/publications Bio Jenny completed her PhD at King's College London in December 2019. Here she investigated the measurement of interoception, it's developmental trajectory and the relationship between interoception, health and higher order cognition. In April 2020 she took up a lectureship position at Royal Holloway University of London and in March 2024 she took up a senior lectureship position at the University of Surrey. Jenny's work on interoception has been recognised by several awards for doctoral contributions (from the British Psychological Society, Experimental Psychology Society and King's College London) and early career prizes (the American Psychological Society Rising Star Award and the Young Investigator Award from the European Society for Cognitive and Affective Neuroscience). Jenny is particularly interested in sex differences in interoceptive abilities, including how these emerge across development and whether they relate to sex differences in mental and physical health. She currently holds a New Investigator Grant from the Medical Research Council for investigating changes in interoception across the menstrual cycle.

The ASBMB Mildred Cohn Young Investigator Award recognizes outstanding research contributions to biochemistry and molecular biology. Nozomi Ando is an associate professor at Cornell University's chemistry and chemical biology department. Her lab works on new structural biology methods, such as diffuse scattering analysis of X-ray diffraction images of protein crystals to obtain information about movement within proteins. Learn more: https://www.asbmb.org/asbmb-today/people/081623/asbmb-names-2024-award-winners.

The Walter A. Shaw Young Investigator Award in Lipid Research recognizes outstanding research contributions in the area of lipids by a young investigator. Judith Simcox is an assistant professor of biochemistry at the University of Wisconsin–Madison. Her lab studies plasma lipids that regulate metabolic disease and explores how these lipids function using lipidomics, genetics, and cellular and molecular biology techniques. Learn more: https://www.asbmb.org/asbmb-today/people/081623/asbmb-names-2024-award-winners.

EPISODE SUMMARY Join scientist and mindset & high-performance coach Claudia Garbutt and accomplished aging researcher José Pedro Castro, PhD, as they discuss aging and health In this episode, we talk about: - What is aging & age-related inflammation - Good inflammation VS bad inflammation - Aging clocks and important biomarkers     Episode NOTES José Pedro Castro completed his PhD in Biomedicine in 2015 by Universidade do Porto Faculdade de Medicina. He then moved to the German Institute of Human Nutrition and joined the Grune Lab (Berlin, Germany) to study how age-related redox and metabolism changes impact the adipose tissue and skeletal muscle.  After completing his aims, he was awarded with the prestigious DFG Max-Kade fellowship and moved to Harvard Medical School (Boston, USA) where he joined the Gladyshev Lab. There, he explored the genetics of aging, age-related diseases and lifespan control from a systems biology perspective.  Recently, and after returning to Portugal, he has joined Logarinho Lab at I3S (Porto, Portugal) after being awarded with the FCT CEEC 5th Edition for Assistant Researcher. Published over 30 articles in peer-reviewed journals such as Cell, Nature Aging or Science Advances. Has received several awards and/or honors, including Early Research Career Award (2010) and Young Investigator Award (2013). He is a reviewer for several scientific journals and a review editor for Redox Biology and Frontiers in Aging. His focus lies on understanding the biology of aging and age-related diseases. Using a combination of experimental and computational approaches he is keen to unravel age-related molecular trajectories leading to chronic diseases.  He is also an assistant professor for Immunology and an invited professor for Biogerontology and Aging and Nutrition. He is involved in several dissemination activities such as the creation of the Portuguese Society for Science and Medicine of Longevity.  On a more personal note, José also dedicates his time to literature by reading as much as he can and writing short fiction stories, but his true desire is to one day write a full novel!   Links: https://www.linkedin.com/in/jos%C3%A9-pedro-castro-phd-92528620   ------------ Click this link to listen on your favorite podcast player and if you enjoy the show, please leave a rating & review: https://linktr.ee/wiredforsuccess   Help me keep this show running and awesome: Hit subscribe and join the tribe! THANK YOU for your support! 

In this episode Chris talks to Gláucia Murta, a postdoc in ML4Q, who was won the cluster's Young Investigator Award. They talk about Gláucia's passion for fundamental questions, device independence and a great outreach project, the podcast O Q Quantico she just launched in her home country, Brazil.

Fan Yang, PhD is an Associate Professor at Stanford University with joint appointments in the Departments of Orthopaedic Surgery and Bioengineering joins OsteoBites to discuss her work on tissue engineering strategies for elucidating OS biology and drug discovery.Fan Yang, PhD is the founder and Director of Stanford Stem Cells and Biomaterials Engineering Laboratory, and also Co-director of Stanford NIH Biotechnology Training Program. Her research seeks to develop hydrogels with unique micro- and nano- scale properties to promote stem cell differentiation, tissue regeneration and immunomodulation, with a focus on musculoskeletal diseases. Her lab also harnesses biomaterials to create 3D cancer models with in vivo-mimicking phenotype and drug responses. Such 3D models could enable discovering novel druggable targets that would otherwise be missed using conventional 2D culture, and enable high-throughput drug screening with reduced cost and time than animal models. Prior to joining Stanford, Dr. Yang received her Ph.D. in Biomedical Engineering from Johns Hopkins University, and then completed a postdoctoral fellowship at MIT under Prof. Robert Langer. In recognition of her innovation, she has been recognized by numerous awards including Fellow of American Institute for Medical and Biological Engineering, MIT TR35 Global list honoree, National Science Foundation CAREER award, Young Investigator Award from Society for Biomaterials, Biomaterials Science Lectureship Award, Young Investigator award from Alliance for Cancer and Gene Therapy, Ellen Weaver Award by the Association for Women in Science, Baxter Faculty Scholar Award, the McCormick Faculty Award, Stanford Asian American Faculty Award, and the Basil O'Connor Starter Scholar Research Award, etc.

Welcome to the Derm Club Podcast, where I recently had the pleasure of hosting Dr. William Damsky, a leading figure in cutaneous sarcoidosis. In this session, Dr. Damsky, from Yale New Haven Hospital and a recipient of the American Academy of Dermatology's Young Investigator Award, shares his extensive knowledge on sarcoidosis. We dive into what cutaneous sarcoidosis is, its causes, and risk factors like genetics and environmental exposures. Dr. Damsky also sheds light on the intriguing roles of epigenetics and occupational factors in sarcoidosis. Join us for this insightful conversation exploring the complexities and current treatments of this multifaceted autoimmune disease. Please SUBSCRIBE to the Derm Club Podcast wherever you like to listen whether on YouTube, Apple, or Spotify. Together, let's explore the fascinating secrets of dermatology and skincare. Connect with me across Social: Twitter: https://twitter.com/drhankopelman Instagram: https://www.instagram.com/doctor.han/ TikTok: https://www.tiktok.com/@drhankopelman Blog: https://www.hannahkopelman.com/blog/ The content of this podcast is for entertainment and educational purposes only. This content is not meant to be a substitute for medical advice or treatment for any medical condition. --- Send in a voice message: https://podcasters.spotify.com/pod/show/hannah-kopelman/message

In this episode, we welcome Amisha Parekh de Campos, PhD, MPH, RN, CHPN to the show where she speaks on the research that she is conducting surrounding people of color in end-of-life care. Amisha speaks on the importance of incorporating race into practice to best serve our minority populations and how we can advocate for our patients of color.    About Amisha: Amisha Parekh de Campos, PhD, MPH, RN, CHPN has a joint appointment as an Assistant Clinical Professor, University of Connecticut School of Nursing, and Quality and Education Coordinator of the Middlesex Health Hospice Program, Middletown, CT. Amisha received her PhD in Nursing from the University of Connecticut (2020), and BS and MPH in Global Health from George Washington University (2001 & 2005). She received her BSN from the University of St. Joseph in 2009; additional certifications include hospice and palliative care (CHPN). Amisha started her career in public health by establishing public health clinics and training community health workers in rural areas of south India and the Dominican Republic. She led initiatives on the prevention of HIV, tuberculosis, and mosquito-borne illnesses with community, government, and private organizations. For the past ten years, Amisha has worked in hospice home care in various leadership roles, including community liaison and clinical supervisor. Currently, she manages research, quality, education, and orientation for the Hospice Homecare program, which serves approximately 150,000 people in Connecticut. In addition, Amisha is an Assistant Clinical Professor at the University of Connecticut, School of Nursing working towards enhancing the palliative care curriculum and education among undergraduate students. She is a Robert Wood Johnson, Future of Nursing Scholar (2017-2020) and Jonas Scholar for Chronic Health (2017-2020). In 2019, Amisha received the 2019 Hospice and Palliative Nurses Foundation Scholarship to fund a study in advance care planning through simulation with registered nurses. She is the 2021 recipient of the Hospice and Palliative Credentialing Center Certified Hospice and Palliative Nurse of the Year and recipient of the 2021 Young Investigator Award from the Connecticut Coalition to Improve End-of-Life Care. Amisha was also featured in the Journal of Hospice and Palliative Nursing. Amisha's program of research focuses on end-of-life care communication. Her dissertation focused on simulation among registered nurses in advance care planning communication. Working at a community health system, she has noticed the disparities in end-of-life care among people of color. With her public health background and working with communities, she would like to assess the barriers and facilitators to end-of-life care and provide interventions to expand EOL services to this population.      

This week, Rachel chats with Oriel FeldmanHall,  Professor of Cognitive, Linguistics, and Psychological Sciences at Brown University. Oriel's lab leverages methods from behavioral economics, social psychology, and neuroscience to explore the neural bases of social behavior, and the role of emotion in shaping social interactions. She has won numerous awards, including the Cognitive Neuroscience Society's Young Investigator Award for outstanding contributions to science, the Association for Psychological Science's Janet Taylor Spence Award for Transformative Early Career Contributions, and the American Psychological Association's Distinguished Scientific Award for Early Career Contribution to Psychology. In this episode, Oriel provides an introduction to the world of affective science, explaining how her team measures and studies emotion. She describes how the emotions that we expect to feel—and the inaccuracies in our predictions—shape our judgments and behavior, and the complex relationship between emotion and depression. We also discuss the hazards of sharing scientific findings on twitter, and how some of the best research questions originate in coffee shops.  JOIN OUR SUBSTACK! Stay up-to-date with the podcast and become part of the ever-growing community

Dr. Alexis “Lekki” Wood is Associate Professor at USDA/ARS Children's Nutrition Research Center in the Division of Pediatrics-Nutrition at Baylor College of Medicine. Research in Lekki's lab aims to better understand how food influences our health. She examines the full chain of changes that occur from the moment food is put into our mouths, trough digestion and absorption of particular molecules, to where those molecules go and how they affect our organs. Outside of work, you can find Lekki working out at the gym and spending quality time with her two children and their German shepherd. She is also a Lego builder and a competitive Pokemon card player along with her son. She received her BSc with honors in Psychology and from the University of Warwick. Afterwards, she completed her Postgraduate Certificate in Education at the University of Cambridge. Lekki enrolled in graduate school at King's College London where she earned her MSc in social, genetic, and developmental psychiatry and her PhD in statistical genetics. Next, she conducted postdoctoral research at the University of Alabama focusing on statistical genetics and epidemiology. Lekki served on the faculty at The University of Texas, Health Sciences Center for about two years before joining the faculty at Baylor College of Medicine where she is today. Lekki has received a variety of awards and honors for her work, including the Young Investigator Award from the International Congress on ADHD and the Young Investigator Award from the Department of Pediatrics at Baylor College of Medicine. In addition, she has received the Scott Grundy Award for Excellence in Metabolism Research and the Mark Bieber Award for Excellence in Nutrition Research, both from the American Heart Association. She was also named a Fellow of the American Heart Association in 2015. In our interview, she shares more about her life and science.

Dr. Staci Leisman is a board certified internist and nephrologist who practices nephrology at Mount Sinai Hospital. She is also an accomplished educator in the Icahn School of Medicine at Mount Sinai. 
Dr. Leisman received her B.A. in English Language and Literature from Yale University, where she graduated magna cum laude and was inducted into Phi Beta Kappa. She received her M.D. from Washington University in St Louis, where she was one of 8 recipients of the Distinguished Scholar Award. She completed her residency in Internal Medicine and fellowship in Nephrology at Mount Sinai Medical Center. As a fellow, she completed research in transplant immunology in the laboratory of Dr. Peter Heeger, which resulted in a Young Investigator Award from the American Society of Transplantation and two oral presentations at the American Transplant Congress. During her fellowship, she co-first authored and was a contributing author on numerous papers. 
Dr. Leisman's clinical duties include caring for patients on dialysis at an outpatient dialysis facility, as well as attending on the inpatient renal service at Mount Sinai Hospital. 
Dr. Leisman has been extensively involved in teaching throughout her career. She currently teaches students at all levels of medical education, including medical students, residents and fellows.  She is the course director for the Human Physiology course in the medical school, and holds a secondary appointment in the Department of Medical Education, where she is a co-director for the medical school curriculum. In her capacity as an educator, she has won numerous awards including Teacher of the Year at North General Hospital, the Edward Ronan Student Council Award at the Icahn School of Medicine, the Institute for Medical Education's Excellence in Teaching Award, the Student Council Lifetime Achievement Award, the JOWMA Outstanding Achievement Award, and the Gold Humanism in Medicine Award. She has been selected for membership in the Institute for Medical Education as a Master Educator. 
Dr. Leisman also serves on the International Association of Medical Science Educators' educational scholarship committee, and serves on the editorial board of Advances in Chronic Kidney Disease, the Journal of the National Kidney Foundation. She is the Deputy Education Director for the Kidney Self Assessment Program (KSAP), the preeminent board preparation tool published by the American Society of Nephrology. _______________________________________________________ Become a JOWMA Member! www.jowma.org  Follow us on Instagram! www.instagram.com/JOWMA_org  Follow us on Twitter! www.twitter.com/JOWMA_med  Follow us on Facebook! https://www.facebook.com/JOWMAorg/ Stay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

Dr. Weizhe Hong is a Professor of Neurobiology, Biological Chemistry, and Bioengineering at the University of California Los Angeles. His research aims to uncover the fundamental neural mechanisms underlying social behavior, with a specific focus on empathy and prosociality. Dr. Hong earned his Ph.D. degree in 2012 from Stanford University and was a Helen Hay Whitney Postdoctoral Fellow at the California Institute of Technology during 2012-2015. In 2016, he joined UCLA as Assistant Professor, and he was promoted to Associate Professor with tenure in 2020 and to Full Professor in 2023. He is also the recipient of a Young Investigator Award from the Society for Neuroscience, an Early Career Award from the Society for Social Neuroscience, a Mallinckrodt Scholar Award, a Vallee Scholar Award, a Searle Scholar Award, a Packard Fellowship in Science and Engineering, a McKnight Scholar Award, a Klingenstein-Simons Fellowship, and a Sloan Research Fellowship.​Link: A Multi-Brain Framework for Social InteractionLink: Neural Basis of Prosocial Behavior

What does the journey look like to evolve from an expert presenter to a sought-after speaker and thought leader? How can you escape what I call “the expert trap” and make the shift into thought leadership? My guest and Thought Leader Academy graduate, Teri DeLucca, PhD, has done exactly this. I know you'll be inspired by Teri! In this episode, Teri and I talk about: Why she started her business a few years ago Her initial reluctance to share personal stories and be vulnerable - and what changed her mind Her desire to escape “the expert trap” and go beyond her comfort zone of academic presentations The impact storytelling and vulnerability has had on her, her business, her customers, and her audiences Why she joined the Thought Leader Academy and what she got out of it The elements we've worked on together to create her signature talk, from incorporating humor and video clips to coming up with an acronym and planting sales seeds for her offer About My Guest: Dr. Teri DeLucca is the Founder and CEO of Impact Early Education, a professional development institute for the preschool industry. She completed a dual PhD in developmental psychology and educational psychology from the University of Florida where her research focused on the cognitive, social, and academic development of children. She previously worked as a research scientist for a children's early literacy intervention program and then accepted an applied position as Vice President of Operations for a system of preschools and extended day programs. Her work has been recognized by multiple awards including the Sigma Xi Women in Science Award, Academic Pediatric Association's Young Investigator Award, the Institute of Education Sciences Randomized Trials Award, and most recently she was recognized as one of the Top 40 Under 40 Business Leaders locally. Dr. DeLucca is a member of the John Maxwell Leadership Team and is a John Maxwell certified speaker. She is also a graduate and certified speaker through the Speaking Your Brand Thought Leader Academy. Dr. DeLucca just completed her Presidency with The Junior Service League of St. Augustine, which is a local women's volunteer organization. She enjoys serving the community both locally and abroad and her favorite volunteer endeavors are serving at a children's home in Guatemala for several years and serving with the Big Brothers Big Sisters program. She has been matched with her “Little” sister Hannah for 18 years now! Above all else, the most important role she has is that of mom to two wonderfully amazing boys, who never let her take life too seriously.  About Us: The Speaking Your Brand podcast is hosted by Carol Cox. At Speaking Your Brand, we help women entrepreneurs and professionals clarify their brand message and story, create their signature talks, and develop their thought leadership platforms. Our mission is to get more women in positions of influence and power because it's through women's stories, voices, and visibility that we challenge the status quo and change existing systems. Check out our coaching programs at https://www.speakingyourbrand.com.  Links: Show notes at https://www.speakingyourbrand.com/338/ Teri's website: https://impactearlyed.com/ Discover your Speaker Archetype by taking our free quiz at https://www.speakingyourbrand.com/quiz/ Enroll in our Thought Leader Academy: https://www.speakingyourbrand.com/academy/    Connect on LinkedIn: Carol Cox = https://www.linkedin.com/in/carolcox Teri DeLucca = https://www.linkedin.com/in/teri-delucca-ph-d-46b296200/  Related Podcast Episodes: Episode 241: The Expert Trap: What Holds Women Back from Thought Leadership with Carol Cox Episode 327: From Expert to Thought Leader: 3 Key Strategies You Need Now to Set Yourself Apart in Our New AI-Driven World with Carol Cox Episode 307: From University Lecturer to Thought Leader with Heather Hausenblas, PhD  

The Young Investigator Award Winners. Danesh Kella, MBBS, FHRS and Jason T. Jacobson, MD, FHRS congratulate the Heart Rhythm 2023 Young Investigator Award winners. This episode was recorded live at Heart Rhythm 2023 in New Orleans, Louisiana. https://www.hrsonline.org/education/TheLead Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stock Ownership: Atlas 5D D. Kella: No relevant financial relationships with ineligible companies to disclose.

Paul A. Offit, MD, is Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children's Hospital of Philadelphia. He is the Maurice R. Hilleman Professor of Vaccinology at the Perelman School of Medicine at the University of Pennsylvania. Dr. Offit is an internationally recognized expert in the fields of virology and immunology, and was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention. He is a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, and a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine and co-editor of the foremost vaccine text, Vaccines. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal. Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq®, recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. Read Dr. Offit's complete bio here: https://www.chop.edu/doctors/offit-paul-a _______________________________________________________ JOWMA Podcast | Ep. 1 How to Fool Yourself Less Often: Medical Decision Making for Regular People https://anchor.fm/jowma/episodes/Ep--1-How-to-Fool-Yourself-Less-Often-Medical-Decision-Making-for-Regular-People-eav2pu _______________________________________________________ Become a JOWMA Member! www.jowma.org  Follow us on Instagram! www.instagram.com/JOWMA_org  Follow us on Twitter! www.twitter.com/JOWMA_med  Follow us on Facebook! https://www.facebook.com/JOWMAorg/ Stay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

Bonnie Ky, MD, MSCE, FACC and Megan Mulholland, MSc, the 2022 JACC: CardioOncology Young Author Achievement Award winner, discuss science and training in the field, career goals and plans, and her original research manuscript on immune therapy and atherosclerosis now online in JACC: CardioOncology.

Join A Cure in Sight to discuss systemic therapies for metastatic uveal melanoma with Dr. Meredith McKean.   We discuss when to use systemic therapies, what is out there besides KIMMTRAK, how to determine a path forward for introducing systemic therapies in metastatic management   McKean received her bachelor's degree from Iowa State University, where the promising athlete ran cross-country and track. During fellowship, McKean studied biomarkers for response to immune checkpoint inhibitors (ICI) in metastatic melanoma, earning her an American Society of Clinical Oncology 2017 Young Investigator Award. She now serves as the director for the Melanoma and Skin Cancer Research Program at the Sarah Cannon Research Institute at Tennessee Oncology.   ANNOUNCEMENTS: Head to our site to register for a 5K Lookin' for a Cure near you! www.lookinforacure.org   Swing for Sight April 22, 2023 REGISTER for SWING FOR SIGHT TODAY: Subscribe to the newsletter to stay in the know Newsletter link   Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org  The Eye Believe Podcast is brought to you by Castle Biosciences. Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.  This podcast was hosted by Danet Peterson and produced by Page Fronczek.

Dr. Alexander Whiting is a neurosurgeon and director of epilepsy surgery for Allegheny Health Network's Neuroscience Institute. He specializes in state-of-the-art epilepsy treatments, including stereoelectroencephalography (SEEG), seizure focus resections, laser ablations, vagal nerve stimulation, and responsive neurostimulation. Additionally, he has clinical interests in complex spine and brain disorders, and offers a range of surgical options and interventions for these conditions. Dr. Whiting completed his residency at the Barrow Neurological Institute in Phoenix, Arizona. He completed his fellowship in epilepsy surgery at the Cleveland Clinic in Cleveland, Ohio, and was awarded the American Epilepsy Society's prestigious Young Investigator Award. Today we speak to Dr. Whiting about SEEG.

Dr. Melik Demirel is a Professor of Engineering Science and Mechanics at The Pennsylvania State University. Melik is fascinated by complexity in living and nonliving systems. He works at the intersection of biology, materials science, and computational science to understand whether patterns in living and nonliving systems follow mathematical and statistical rules, to determine the underlying physical basis of these patterns, and identify relevant mechanisms. He likes listening to music to engage the creative aspects of his mind. Some of his favorites are composers like Beethoven and Rachmaninov. Melik's wife plays piano, and his son plays piano and cello, so music is a big part of their lives. Malik received is B.S. and M.S. in Engineering from Boğaziçi University in Turkey and was awarded his PhD in Materials Science and Engineering from Carnegie Mellon University. Afterwards, Melik conducted postdoctoral research at Los Alamos National Laboratory and was awarded an Alexander von Humboldt Fellowship in Molecular Biology at the Max Planck Institute in Gottingen, Germany. He accepted a faculty position at Penn State in 2003. Melik was a recipient of the Young Investigator Award from the Office of Naval Research within the Department of Defense, was selected as a Wyss Institute Visiting Scholar at Harvard University, and was awarded the Outstanding Research Award from Penn State, among other honors during his career. In this episode, he tells us about his experiences in life and science.

Dr. Charles Ryan, president and CEO of the Prostate Cancer Foundation (PCF), joins ASCO Daily News Editor-in-Chief Dr. Neeraj Agarwal, of the University of Utah Huntsman Cancer Institute, to assess impactful prostate cancer research from the PCF's recent conference and discuss Dr. Ryan's vision for the future, including increasing access to cutting-edge care. TRANSCRIPT Dr. Neeraj Agarwal: Welcome, to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the editor-in-chief of the ASCO Daily News, and director of the Genitourinary Cancers Program at the University of Utah Huntsman Cancer Institute. Today, we'll be discussing compelling research that was featured at the recent Prostate Cancer Foundation Scientific Retreat, and I'm very pleased to welcome Dr. Charles Ryan, the president, and CEO of the Prostate Cancer Foundation. Our full disclosures are available on the transcript of this episode, and disclosures relating to all episodes of the ASCO Daily News Podcast are available on our transcripts at: asco.org/podcasts. Dr. Ryan, thank you for taking the time to be with us today. Dr. Charles Ryan: Dr. Agarwal, thank you. It's my pleasure to be with you. Dr. Neeraj Agarwal: So, Dr. Ryan, before I discuss the PCF meeting, I would like to ask you, what made you move to the PCF as the president and CEO when you had a flourishing career as a division chief of a large academic program, and as one of the top and internationally recognized investigators in prostate cancer? Dr. Charles Ryan: Well, thanks. That's a fair question, I guess. And it took me about three minutes to make the decision when I was offered the position, simply because the Prostate Cancer Foundation has been one of my intellectual homes for my entire career. I've been at the University of Wisconsin, Memorial Sloan Kettering Cancer Center, UCSF, and the University of Minnesota, and all those institutions were affected by the Prostate Cancer Foundation, or previously, CaP CURE. So, I was involved in their research during my time at all those institutions. In addition to my own personal legacy with the PCF, but more importantly, is the fact that it is an organization that funds the deepest scientific inquiry into prostate cancer and the ways that it can cause suffering and death for men with the disease and has made tremendous progress in identifying factors that lead to that lethality. It's also a community of scholars, a community of researchers, that is a platform really for collaboration. And it's also an organization with a world reach - we fund research in 28 countries around the world, and we fund research going from the scope of very basic research to correlative research, to quality of life, and health services research. Dr. Neeraj Agarwal: That is truly impressive and inspiring. So, what is the mission of the Prostate Cancer Foundation formally? Dr. Charles Ryan: Formally, it's pretty simple. The mission of the Prostate Cancer Foundation is to reduce the death and suffering from prostate cancer. Dr. Neeraj Agarwal: So, the 29th PCF Scientific Retreat was recently held on October 27 to October 29th in Carlsbad, California. What were the goals and objectives of this meeting? Dr. Charles Ryan: The meeting, we call it the retreat, it's an annual event and it always has several goals. One is, it's where we announce and hand out, if you will, our awardees of our various awards that we give. It's also a reporting-in process where those who have been using PCF funding are called to come and discuss their work. We also want it to be an open forum for individuals to come and interact - it's really a collaboration and an interaction vehicle as much as anything. So, when you come to our scientific retreat, we all stay at the same hotel, we all share meals together, nobody goes out for dinner. You don't leave the campus, essentially, of the hotel where we are. We have many, many round tables set out, it's designed to be interactive. We have a big room where people are giving their talks, but if you step outside of the room, there are likely to be many, many conversations happening, and those conversations range from collaborations being formed to people looking for jobs, to people getting advice and mentoring, and even people sharing, as I've done over the years, compelling and challenging patient stories around prostate cancer, and really engaging in what communities do - which is, share ideals, share a mission, and share a passion for what they do. Dr. Neeraj Agarwal: Very interesting. Very inspiring. Please tell us some of the highlights of the meeting. Dr. Charles Ryan: Sure. Well, there are many highlights. There are many things happening in prostate cancer research. Most notably, there are a number of papers and investigators that are looking at how prostate cancer evolves, and probably the most significant set of observations that have been made in the field in the last decade, have been understanding the diverse and numerous mechanisms that underlie the evolution of prostate cancer from a disease that responds to hormonal manipulation, to one that becomes resistant to hormonal manipulation. And so, a lot of the work that's happening now is identifying, for example, the evolution of neuroendocrine prostate cancer, or mixed types of prostate cancer, or this sort of evolution of it under constant therapy. And that is allowing the exposure of new targets that we can exploit for new therapy development, and that feeds into some of the grant-making process that's going on in the background. And so, you have a lot of individuals who are looking at this or that mechanism pathway related to disease resistance that they can exploit, and whether they can create small molecules to do that, or antibodies to do that, et cetera. At the same time, we have a strong component of discussion of how prostate cancer affects different populations. So, we had some really nice talks looking at healthcare disparities and different populations across the world, and how they're affected by prostate cancer, and how care delivery may be impacted in those groups of patients. And then you have topics ranging around survivorship and other factors that are looking at what is life like for a man with advanced prostate cancer, which is in many cases, you know, men who get prostate cancer, who have recurrent disease, who end up going on systemic therapy are frequently on the treatment for 5, 10, 15 years. And so, survivorship, and how they live their life, and what the complications are of that treatment, is tremendously important because it's such a daily experience for these men undergoing treatment. Dr. Neeraj Agarwal: So, how does the Prostate Cancer Foundation support and build the next generation of prostate cancer researchers? Dr. Charles Ryan: Right. So, the PCF supports the next generation in a very specific way, in addition to the informal way of bringing people together and inducing collaborations. We have a program called the Young Investigator Program. It started formally in 2008, but before that, there were one-off, if you will, Young Investigator Awards being given. So, our Young Investigator Awardees receive $75,000 per year to support their work, and we awarded 34 of those this year. The range is somewhere from 25 to 34 per year. We get over 100 applications for them every year. It's a straightforward application - they need to have a project that's going to be about three years in length, they need to be mentored, and they are best served by describing a mentorship plan for themselves and how that mentorship relationship will help them grow in their careers. Now, once you become a Young Investigator, it's not that we just write you a check and wish you well, we do that, but we also have annual check-ins. So, we try to visit the sites of our Young Investigators, see them in their home institution, and meet with their colleagues and their mentors. And that's one of the things I do, or Howard Soule does-- Howard Soule, is our chief scientific officer, one of those things we try to do. We also bring them to the scientific retreat that we just had last week, and we have them present their data. So, a vast number of the individuals who are presenting at the scientific retreat are in fact, Young Investigators, or they were Young Investigators when they started the projects that they are presenting. And then, the other thing we do is we have another retreat specifically for the Young Investigators, and that's called the Coffey-Holden Retreat, and that's named after Don Coffey, the late researcher from Johns Hopkins, who is really considered to be one of the grandfathers of prostate cancer research, and Stuart or Skip Holden, who is one of the founders of the Prostate Cancer Foundation, and a urologist at UCLA. So, that event that we do is designed for people to come to give highlights of the work that they're doing; it's designed to be incredibly interactive. In fact, we have 15 or so minutes of presentation, followed by sometimes 25 minutes of questions for each presenter. There's always a line of people who are waiting to ask questions, and it's designed to engage and have that dialogue with the Young Investigators, to make their science better, and to get it known. And so, the Young Investigator Program, it's about 30 individuals per year on average, and the average age is about 30. Many of these are postdoctoral PhDs, and many of them are fellows, or early-stage faculty, MDs. And I like to think that if somebody's going to work until the age of 70, we're stimulating, or launching a 40-year career with these Young Investigator awards. So, I like to think that if we give 25 out, times 40 years, that's 1,000 years of research that we're sort of stimulating with this Young Investigator program. And I bring that up for the reason that we're very proud of the fact that many of our Young Investigators may start out in prostate cancer, and their ideas, their science, takes them elsewhere. And that's what science does. And we, of course, are very, very focused on solving the problem of prostate cancer, and we want people to do that. But we also understand that by launching a scientist, by launching a scientific career, you may end up with people going off in different directions. And so, we have many examples of that. And in my talk this year, I actually highlighted a person who, let's say she won an investigator award when she was young, it was before the formal Young Investigator Award was named, and this was a person who is creating conjugates for the delivery of chemotherapy to prostate cancer cells. And this was Carolyn Bertozzi up at UC Berkeley, and she just won the Nobel Prize. She didn't win the Nobel Prize for research she did on prostate cancer, but at some point, at one point in her career, this was a direction she was going, and she got two grants from us in 1999 and 2000, that helped her work continue on and go the direction that it did. Dr. Neeraj Agarwal: Yeah. And congratulations. Dr. Charles Ryan: Sure. I'll take credit for that one. Dr. Neeraj Agarwal: Being the President and the CEO, you deserve the credit. Dr. Charles Ryan: Sure. That's my job. Dr. Neeraj Agarwal: So, we are coming to the end of the interview, but let me ask you this; the prostate cancer field is so constantly evolving. What is your vision for PCF going forward? Dr. Charles Ryan: Well, my vision for the organization is that we are going to continue on our mission to reduce the death and suffering from prostate cancer. But that's a fairly general statement, and one of the ways you can do that is you can research cancer at a molecular level, and you could try to develop new therapies - we're going to continue to do that. But there's also a real problem, especially, in the United States, and actually globally, with individuals with prostate cancer who are not receiving the cutting-edge care, not receiving the cutting-edge therapy. We have some data that in the United States, maybe upwards of 50% of men with metastatic hormone-sensitive prostate cancer are not getting the therapies that are supported by the latest findings from randomized phase III trials. And this may be for economic reasons, it may be communications or an education deficit with their treating clinicians, and there may be other factors as well. So, as we think about the vision of this, we need to be mindful of that, because if we only focus on studying the cancer molecularly, and we don't address what's happening on the other end, then we're not completing the story, and we're not completing the mission. And so, I've started calling Prostate Cancer Foundation the Global Public Square of Prostate Cancer, because I think of four sides of that square - funding research, as of what we just got done talking about, education and communication, is another one, and we do that in the same way that you are doing this today - through podcasts, and web content, and in-person meetings, as well as applied discovery, which is helping our researchers take their discoveries or their findings out into the clinic. Now, you might think, "Well, that's a small molecule, becoming a company going into a phase I clinical trial." Certainly, that's part of it, but it's also the epidemiologist who is making observations about diet and exercise, who is then empowered to do a clinical trial of exercise and diet intervention. It's also the health services researcher who is able to use their data to go talk to payers or talk to organizations about how care may be delivered differently. So, that's applied discovery. And then finally, supporting the patient is part of what we do. So, we also hold patient webinars every month, we've held patient summits at various points around the country where we bring patients together and talk to them about the latest research or about the factors we've discussed, such as survivorship, or quality of life after treatment, or treatment complications, and things like that. Dr. Neeraj Agarwal: That's wonderful. Thank you so much for sharing your insights. Any final remarks, Dr. Ryan? Dr. Charles Ryan: Dr. Agarwal, thank you so much. It's always a pleasure to speak to another Genitourinary Oncologist, of course, about the field, and the opportunity to talk about the Prostate Cancer Foundation and what we're doing, and the directions we are trying to grow. We've had a great collaboration with ASCO over the years, and I hope that that continues as well. I hope anybody who is interested would come and visit us at: pcf.org, and they can also check us out on: urotoday.com, where we have a lot of content that might be of interest to them. Dr. Neeraj Agarwal: Thank you, Dr. Ryan, for taking the time to be with us on the ASCO Daily News Podcast today. And thank you to our listeners for joining us today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe, wherever you get your podcast. Thank you very much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement. Follow today's Speakers: Dr. Neeraj Agarwal @neerajaimms Dr. Charles Ryan @charlesryanmd Want more related content? Listen to our podcast on therapeutic advances in prostate cancer and other GU cancers.   Advances in Genitourinary Cancers at #ASCO22 Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Neeraj Agarwal:  Consulting or Advisory Role: Pfizer, Medivation/Astellas, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, Gilead Sciences  Research Funding (Inst.): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck , Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas   Dr. Charles Ryan: Honoraria: Janssen Oncology, Bayer Consulting or Advisory Role: Bayer, Dendreon, AAA, Myovant Sciences, Roivant, Clovis Oncology  

Welcome back to our Generation COVID series where we're exploring the impact of the pandemic on pregnant and postpartum parents. In this episode, we're focusing on childbirth and parent mental health. Dr. Amanda Zelechoski interviews Dr. Sharon Dekel and three parents. Together they discuss the pandemic impact on child birthing experiences, the increase in traumatic child births, and the overall mental health challenges new parents have faced in these uncertain times.Additional ResourcesPreeclampsia Foundation7 Symptoms Every Pregnant Woman Should Know (Preeclampsia Foundation)1-833-9-HELP4MOMS – National Maternal Mental Health HotlineLínea Nacional de Asistencia de Salud Mental Materna Para Mamás Primerizas y EmbarazadasFor some women giving birth in the pandemic, the trauma led to personal growth by Juli Fraga (The Washington Post)Meet Our GuestsDr. Sharon Dekel is Assistant Professor of Psychology in the Psychiatry Department at Harvard Medical School and Director of the Postpartum Traumatic Stress Laboratory at Massachusetts General Hospital. She is known internationally for her research on childbirth-related posttraumatic stress. Her work, which has been continually supported by the National Institute of Health (NIH), brings together clinical and developmental psychology, psychophysiology, neuroscience, and machine learning to develop novel screening and interventions for at-risk individuals. Her current project examines the maternal brain and the neural profile that underlies childbirth-related PTSD. She also serves as the principal investigator of the Mothers Wellness study that assesses traumatic childbirth in the outbreak of the COVID-19 pandemic.Dr. Dekel is a two time recipient of the Brain and Behavior Research Foundation's Young Investigator Award; of Harvard's Mind Brain Behavior Awards; and of Mass General's Executive Committee On Research Awards. She was awarded the MGH's Claflin Distinguished Scholar Award for Women in Science and the Postpartum Support International Susan A. Hickman Memorial Research Award for excellence in scientific work on postpartum mental health. Dr. Dekel earned a Ph.D. in Clinical Psychology from Columbia University. She then completed her clinical internship training at Columbia Medical Center and continued to a research postdoctoral fellowship in a lead trauma lab in Israel. Her prior work on the human capacity to thrive in the wake of trauma is considered pioneering in the field. Dr. Dekel also has a private practice in which she treats peripartum individuals.Many thanks to parents Jillian, Stacey, and Dan for sharing their pandemic childbirth and mental health stories in this episode.

Dr Noemi Roy and Dr Roberta Russo present a podcast on the The use of next-generation sequencing in the diagnosis of rare inherited anaemias: A Joint BSH/EHA Good Practice Paper   Dr Roy and Dr Russo discuss the good practice paper in three main parts: 1) Focus on rare anaemias: ( Diamond-Blackfan Anaemia, Congenial dyserythropoietic anaemia (CDA), Sideroblastic anaemia and Red cell membrane/cation leaking and enzyme disorders 2) Next generation sequencing (NGS) 3) How and why we need to interpret genetic variants carefully  The use of next-generation sequencing (NGS) in the diagnosis of rare inherited anaemias is increasingly common, as evidenced by a growing number of publications describing its clinical utility.1-6 Excluding disorders of globin synthesis, rare anaemias include Diamond–Blackfan anaemia (DBA), congenital dyserythropoietic anaemias (CDA), congenital sideroblastic anaemias (CSA) and disorders of red cell membrane and enzymes. Other forms of genetic anaemias can also be considered while establishing NGS panels, in particular genetic syndromes where anaemia comprises one of the constellation of symptoms. Dr Noemi Roy is a Consultant Haematologist at Oxford University Hospitals NSH Foundation Trust and honorary senior clinical lecturer in haematology at the University of Oxford. She is a BSH General Haematology Task Force member and Chair for the Guidelines Executive committee for the European Hematology Association. She is the rare anaemia representative at the National Haemoglobinopathy Panel. Her main interests are haemoglobinopathies and rare inherited anaemias, and in particular the genetic investigation of inherited anaemias, including whole genome sequencing. Dr Roberta Russo is an assistant professor in medical genetics at the University of Naples "Federico II". She has dealt with the study of the genetics of rare disorders, particularly hereditary anaemias, since 2008. Her main interest was the study of Congenital Dyserythropoietic Anaemias (CDAs), mainly CDA type II, genetics and genomics of red cell anaemias and blood cell defects . She contributed first hand to the identification of the causative genes of rare anaemias. Subsequently, she became one of the leading scientists for the genetics and epidemiology of CDAs. Since 2015, she has been dealing with the application of next generation sequencing to the clinical and medical definition of patients affected by this conditions. In 2011, she won the Young Investigator Award by the American Journal of Hematology for her study on the epidemiology of this disorder.

Dr. Mitra Ray is a woman on a mission. She is fiercely committed to being a trusted guide for those who love life, those who want to be healthy and happy, and those who want to live to dance at their grandchildren's wedding. If you are looking for a proven professional who can guide you to better health - with practical and doable solutions that are easy on the wallet in these changing and busy times - then you have come to the right place. With over 30 years of experience, she has helped people achieve remarkable success in feeling better. Dr. Ray received her Bachelor of Science at Cornell University and her PhD from Stanford Medical School. She is the recipient of many NIH grants and the Young Investigator Award from the Federation of American Societies in Experimental Biology. Her research has been published in such prestigious journals as Science, Proceedings of the National Academy of Sciences and the Journal of Cell Biology. Audiences in 4 continents have enjoyed her award-winning books, audios and lectures on nutrition, stress reduction, brain function and longevity. She is the CEO and CoFounder of rREST Inc, an emotional wellness startup company committed to bringing a disruptive technology in neuroemotional psychology to millions and help them reprogram childhood stress patterns. rREST has received a Google Social Impact Grant to help bring awareness of this technology to the public.

In this episode, I am joined by 2 women who have been in my world and my life for quite a long time, and who have so much knowledge and wisdom to share – Nicole Scott & Dr. Mitra Ray. Nicole Scott is a Holistic Nutritionist, Pro Aging Advocate, Author, International Wellness speaker, Global Network Marketing Professional and mom of 2 teenage girls. Dr. Mitra Ray, with over 30 years of experience, has helped people achieve remarkable success in looking and feeling better. Dr. Ray received her Bachelors of Science at Cornell University and her PhD from Stanford Medical School. Today we chat about all things micronutrition and how to create opportunity and abundance in your life. Are you ready for this eye-opening conversation?   Connect with us - Thank you for joining us today. If you could do me the honor of hitting the subscribe button, leaving a review, sharing this podcast with a friend, or tagging me on social media when you visit The Simplicity Sessions Community on Facebook or @jennpike on Instagram, I would be forever grateful. Connect with our Guests - Nicole Scott Nicole Scott is a Holistic Nutritionist, Pro Ageing Advocate, Author, International Wellness speaker, Global Network Marketing Professional and mom of 2 teenage girls. Website: nicolescott.ca Grab the Gray Hair Transition Guide: https://aw1a22c4.aweb.page/p/e9acb6ea-6e16-499e-893e-c08fcd597f30 Instagram: @gorgeousgreymovement @designasweetlife   Dr. Mitra Ray With over 30 years of experience, she has helped people achieve remarkable success in looking and feeling better. Dr. Ray received her Bachelors of Science at Cornell University and her PhD from Stanford Medical School. She is the recipient of many NIH grants and the Young Investigator Award from the Federation of American Societies in Experimental Biology. Her research has been published in such prestigious journals as Science, Proceedings of the National Academy of Sciences and the Journal of Cell Biology. Audiences in 4 continents have enjoyed her award winning books, audios and lectures on health, beauty, brain function and longevity. Her mission and commitment is to educate and inspire people about how plant-based, whole foods create simple, sustainable beauty, mental clarity and vitality. Website: drmitraray.com Instagram: @drmitraray Learn more about the products and supports I recommend from some of our amazing partners - Eaton Hemp is my favourite CBD and hemp company. They are a hundred percent organic, they're unfiltered, and they are third-party tested. To experience Eaton Hemp, use the discount code JENNPIKE20 at eatonhemp.com/jennpike to save 20% off your order. St Francis Herb Farm education includes webinars, blogs and articles on important topics including the plant medicines that they create to promote women's health by targeting digestion, allergies, immune support, heart health, brain health, and sleep. I use and recommend their products and you can use the code JENNPIKE15 at checkout to save 15% off your order. GoodJuju makes all-natural, plastic-free home & body products that are good for you and good for the planet. Use JENNPIKE10 for 10% off your order. Skin Essence is Canadian-founded, organic, non-GMO, and does not test on animals; this company is one that we love and have around the house. You can even talk to the company to get advice on which products may be right to try first. Save 15% off your first order with the code JENNPIKE15 and use code JENNPIKE10 to save 10% off every order after that.

Discussion of a new, early phase clinical trial for patients with metastatic osteosarcoma targeting the DNA damage repair pathway. Dr. Vishu Avutu attained his M.D. from the University of Texas Southwestern Medical School and began his research endeavors with the Pediatric Oncology Education Program at St. Jude Children's Research Hospital; finding a passion for working with adolescents and young adults, Vishu matched to the internal medicine-pediatric residency at Harvard's Brigham and Women's/Boston Children's Hospitals. In addition to serving as Chief Resident, Vishu helped develop and launch the Center for Adolescent and Young Adult Oncology at the Dana Farber Cancer Institute. He then completed his medical oncology fellowship at Memorial Sloan Kettering Cancer Center. He is a co-founder of MSK's Adolescent and Young Adult Oncology Program, where his work has garnered MSK's Patient and Family Centered Care Grant Initiative and the Young Investigator Award from the American Society of Clinical Oncology. He is an assistant attending in the Departments of Medicine and Pediatrics and cares for AYAs with sarcomas.

Today on Breast Cancer Conversations I'm joined by Dr. Bardia, a Board Certified Medical Oncologist interested in developing successful, targeted and personalized therapies to improve the outcomes of patients and families affected by breast cancer. Dr. Bardia is involved in clinical development of tumor genotyping, as well as circulating tumor cells to facilitate accurate diagnosis, therapy selection, and real time monitoring of breast cancer. Dr. Bardia is the primary investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer, and is the recipient of the Young Investigator Award from ASCO Conquer Cancer Foundation. I am also joined by two other amazing women, Janice Cowden and Keegan Hitchcock, both living with metastatic TNBC. Janice was diagnosed with stage four metastatic triple negative breast cancer in 2016. With a 20 plus year background in nursing, science, research and studying disease, it is no surprise that Janice became a Patient Advocate. Her advocacy work has included working with organizations like METAvivor, Living Beyond Breast Cancer, ABCD after breast cancer diagnosis, among others. I am also so excited because I am joined by Keegan Hitchcock. Keegan is 41 years old, born and raised in Florida, where she had a professional career as a face and body painter for over 20 years. Her interests include reading and consuming lots of podcasts, including anything from spooky stories and humor, to the lesser known history, critical thinking and science. She loves watching and discussing nerdy TV shows and movies with friends, roller-skating, and spoiling her two cats. She now lives in Maryland near family where she continues to work at a national health food store doing price integrity. Her original diagnosis was in May of 2019 with stage three triple negative invasive ductal carcinoma.  As of April 2021, she has been re-diagnosed with a recurrence stage four metastatic triple negative breast cancer.Welcome to the conversation.

Dr. Paul A. Offit, MD, (https://www.paul-offit.com/) is an internationally recognized expert in the fields of virology and immunology, Co-Inventor of a landmark vaccine for the prevention of Rotavirus gastroenteritis, and holds multiple titles including - Director of the Vaccine Education Center at Children's Hospital Of Philadelphia (CHOP), Maurice R. Hilleman Chair of Vaccinology and Professor of Pediatrics, Perelmann School of Medicine, University of Pennsylvania, and Adjunct Associate Professor, The Wistar Institute of Anatomy and Biology. Dr. Offit was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention, a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine, and co-editor of the foremost vaccine text, Vaccines. Dr. Offit is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal. Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of a landmark rotavirus vaccine recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In addition, he has received numerous other awards and honors for his groundbreaking work. Dr. Offit is also an author of many books including, but not limited to: Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases, Overkill: When Modern Medicine Goes Too Far, The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis, Breaking the Antibiotic Habit, Do You Believe in Magic, and his most recent, You Bet Your Life: From Blood Transfusions to Mass Vaccination, the Long and Risky History of Medical Innovation.

There's no better way to kick off September as the Pain Awareness Month than bringing you a conversation with Dr. Kanwaljeet S. Anand, whose research took the medical world by storm, even risking his license, as he sought out to answer the question of; what if we give children anesthesia and analgesia?  I truly believe that he is the reason why my career as a pediatric pain and palliative care physician exists today and serves as an available path for many healthcare professionals. In this episode,  Dr.  Anand, a professor of Pediatrics, Anesthesiology, Perioperative, and Pain Medicine at Stanford University School of Medicine, describes his groundbreaking research back in the 80s, when a popular held belief was that babies don't feel pain!  With the findings  and intervention offered in his RCT, they were able to cut down the infant mortality rates by half.  It is the work of doctors like him that paved the path for someone like me to practice pediatric pain management as a specialty-- hoping to save and improve the lives of many more children by debunking the fallacies that still surround children's pain and its management.   Takeaways In This Episode   What fueled Dr. Anand's desire to research perioperative care for infants His hypothesis around morbidity and mortality of neonates and infants undergoing surgeries, relationship to anesthetic management  Conducting the randomized controlled trial study and its results that changed the history and trajectory of childrens pain and perioperative management Sometimes it's worth picking the fights How his study gained momentum and changed how the healthcare world approaches pain management for children and infants When and how infants develop the ability to feel pain The long-term consequences of poorly or inadequately  managing children's pain Changing the minds of colleagues who perpetuate the belief that children are “hardy” and will “get over it” Dr. Anand's message to the audience   Links Connect with Dr. Kanwaljeet S. Anand: Stanford Profile LinkedIn Love, Pain, and Intensive Care. K.J.S. Anand, Richard W. Hall Clinicians' Pain Evaluation Toolkit Proactive Pain Solutions   About the Guest    Kanwaljeet S. Anand, MBBS, MD, D Phil, FRCCM   He is currently the professor of Pediatrics, Anesthesiology, Perioperative, and Pain Medicine at Stanford University School of Medicine. He directs the pain and stress neurobiology lab, the Jackson Vaughan Critical Care Research Fund, and he serves as the Editor of the journal Pediatric Research and is the Division Chief for Pediatric Critical Care at the Department of Pediatrics at Standford School of Medicine. He graduated from M.G.M. Medical College, Indore (India). He received the D.Phil. degree as a Rhodes Scholar at the University of Oxford, followed by a post-doctoral fellowship at Harvard Medical School, a categorical Pediatrics residency training at Boston Children's Hospital, and a Critical Care Medicine fellowship at Massachusetts General Hospital in Boston. He is the recipient of innumerable awards, including the Dr. Michael Blacow Award from the British Pediatric Association in 1986, the Pediatric Resident Research Award from the American Academy of Pediatrics, the inaugural Young Investigator Award in Pediatric Pain from the International Association for Study of Pain in 1994, the Jeffrey Lawson Award for advocacy of children's pain relief, the highest recognition in pediatric pain medicine in the United States. He's also been awarded many awards across Europe in many countries such as the Nils Rosén von Rosenstein Award from the Swedish Academy of Medicine and the 2015 Journées Nationales de Néonatologie Address at The Pasteur Institute to name a few. For his dedication and work in the field of pediatric pain management, he is considered a world authority on pain and stress in newborns and pain management in infants. 

In Episode 12 of Bladder Cancer Matters, Rick Bangs's special guest is Samuel L. Washington III, MD, MAS, of the University of California San Francisco Department of Urology. Dr. Washington is Assistant Professor of Urology, Goldberg-Benioff Endowed Professorship in Cancer Biology, and a recipient of BCAN's Young Investigator Award. Rick and Dr. Washington discuss: Why should patients get a second opinion? Are there ever good reasons to NOT get a second opinion? Will my doctor support me getting a second opinion? What do you/should you tell the patient as a clinician when you hear them say they want to do this? What if the first and second opinions disagree?  

In this episode, I talk with Professors Kristen Bottema-Beutel and Micheal Sandbank, who have done a systematic review and meta-analysis of 151 group design studies of interventions for young autistic children. For this work, Dr. Sandbank was awarded the Young Investigator Award in 2021 from the International Society of Autism Research. Drs Bottema-Beutel and Sandbank … Continue reading On conflicts of interest in autism research: Interview with Kristen Bottema-Beutel and Micheal Sandbank

Centosessantasettesima puntata della trasmissione "Generazione Mobile" di Radio 24, il primo "passaporto radiofonico valido per l'espatrio". In questa puntata: - Francesca Barbieri, giornalista de "Il Sole 24 Ore", torna a segnalarci le più recenti opportunità di formazione e lavoro all'estero, all'interno della rubrica Toolbox; - Patrizia Mondello, ricercatrice 35enne nel settore oncologico negli Stati Uniti, fresca vincitrice dello "2020 Young Investigator Award" dell'ISSNAF, ci spiega come avviare una carriera di successo nella ricerca medica Oltreoceano; - Eures Italia ci aggiorna sulle prossime opportunità e selezioni per lavorare in Europa; - in Internet Point vi parliamo di un progetto, che mira a portare la cultura italiana nelle case dei connazionali all'estero, attraverso i libri. O meglio, i libri per bambini. Il suo nome è "Sgrunf - Kids Box": con noi la co-founder Anna Sommavilla. CONNETTITI CON "GENERAZIONE MOBILE" Studiate/lavorate/siete imprenditori all'estero? E siete "under 40"? Avete una storia da raccontare e consigli preziosi da dare per cogliere opportunità oltreconfine, sfruttando le occasioni di mobilità internazionale?Scrivete a: generazionemobile@radio24.it Oppure, avete domande da porre su come studiare/fare stage/lavorare/avviare start-up all'estero?Inviatele a: generazionemobile@radio24.it Infine, avete un sito/blog all'estero, nel quale fornite consigli pratici su come trasferirsi nel vostro attuale Paese di residenza? O avete scritto un libro su questo tema?Segnalateci tutto, sempre a: generazionemobile@radio24.it

Centosessantasettesima puntata della trasmissione "Generazione Mobile" di Radio 24, il primo "passaporto radiofonico valido per l'espatrio". In questa puntata: - Francesca Barbieri, giornalista de "Il Sole 24 Ore", torna a segnalarci le più recenti opportunità di formazione e lavoro all'estero, all'interno della rubrica Toolbox; - Patrizia Mondello, ricercatrice 35enne nel settore oncologico negli Stati Uniti, fresca vincitrice dello "2020 Young Investigator Award" dell'ISSNAF, ci spiega come avviare una carriera di successo nella ricerca medica Oltreoceano; - Eures Italia ci aggiorna sulle prossime opportunità e selezioni per lavorare in Europa; - in Internet Point vi parliamo di un progetto, che mira a portare la cultura italiana nelle case dei connazionali all'estero, attraverso i libri. O meglio, i libri per bambini. Il suo nome è "Sgrunf - Kids Box": con noi la co-founder Anna Sommavilla. CONNETTITI CON "GENERAZIONE MOBILE" Studiate/lavorate/siete imprenditori all'estero? E siete "under 40"? Avete una storia da raccontare e consigli preziosi da dare per cogliere opportunità oltreconfine, sfruttando le occasioni di mobilità internazionale?Scrivete a: generazionemobile@radio24.it Oppure, avete domande da porre su come studiare/fare stage/lavorare/avviare start-up all'estero?Inviatele a: generazionemobile@radio24.it Infine, avete un sito/blog all'estero, nel quale fornite consigli pratici su come trasferirsi nel vostro attuale Paese di residenza? O avete scritto un libro su questo tema?Segnalateci tutto, sempre a: generazionemobile@radio24.it

Yes I know I probably ruffled some feathers but to those who got upset, I say how can you help them see if you refuse to talk to them? And it seems everyone, has been trying to get this interview but I do my bet to Lead with Love and be nonconfrontational and respectful which has led to me be able to actually speak cordially with Paul on many occasions. Folks be the change you want to see is all I can say. I will never Lose hope that Paul will see the truth along with the many others I am trying to wake up. Paul A. Offit, MD is the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia as well as the Maurice R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, and a Research Career Development Award from the National Institutes of Health. Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC; for this achievement Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases; and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In 2009, Dr. Offit received the President's Certificate for Outstanding Service from the American Academy of Pediatrics. SEE FULL BIO ON FACEBOOK EVENT wouldn't fit lol

Yes I know I probably ruffled some feathers but to those who got upset, I say how can you help them see if you refuse to talk to them? And it seems everyone, has been trying to get this interview but I do my bet to Lead with Love and be nonconfrontational and respectful which has led to me be able to actually speak cordially with Paul on many occasions. Folks be the change you want to see is all I can say. I will never Lose hope that Paul will see the truth along with the many others I am trying to wake up. Paul A. Offit, MD is the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia as well as the Maurice R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, and a Research Career Development Award from the National Institutes of Health. Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC; for this achievement Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases; and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In 2009, Dr. Offit received the President's Certificate for Outstanding Service from the American Academy of Pediatrics. In 2011, See Facebook for full Bi

I will be interviewing none other than Dr. Paul Offit. Yes I know I will ruffle many feathers but to those who get upset I say how can you help them see if you refuse to talk to them. And it seems everyone, has been trying to get this interview but I do my bet to Lead with Love and be nonconfrontational and respectful which has led to me be able to actually speak cordially with Paul on many occasions. Folks be the change you want to see is all I can say. I will never Lose hope that Paul will see the truth along with the many others I am trying to wake up.  Paul A. Offit, MD is the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia as well as the Maurice R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, and a Research Career Development Award from the National Institutes of Health. Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC; for this achievement Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases; and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In 2009, Dr. Offit received the President's Certificate for Outstanding Service from the American Academy of Pediatrics. SEE FULL BIO ON FACEBOOK EVENT wouldn't fit lol

Dr. Roshan Cools is a Professor of Cognitive Neuropsychiatry in the Department of Psychiatry of the Radboud University Nijmegen Medical Centre and a Principal Investigator of the Donders Institute for Brain, Cognition and Behaviour (Centre for Cognitive Neuroimaging) in the Netherlands. She received a Masters degree in Experimental and Neuropsychology from the University of Groningen in the Netherlands as well as a MPhil degree and PhD in Experimental Psychology from the University of Cambridge. Afterward, she worked as a Junior Research Fellow at St. John's College and the Royal Society Dorothy Hodgkin Postdoctoral Research Fellowship at the University of Cambridge. She traveled to the University of California, Berkeley for a postdoctoral fellowship and then served briefly as a Royal Society University Research Fellow back at the University of Cambridge before accepting her position at the Donders Institute and the Radboud University in nijmegen. She has received a number of personal awards, including the James McDonnell Scholar Award (2012) and the Young Investigator Award of the Cognitive Neuroscience Society (2012). Roshan is with us today to tell us all about her journey through life and science.